CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 287 enrolled
Drug / intervention
Tezepelumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05329194
NCT05329194Phase 4Completed
CompareCT.gov

A Multicenter, Single-arm, Open-label, Post-Authorization, Phase 4 Effectiveness and Safety Study of Tezepelumab in Adult and Adolescent Participants With Severe Asthma Including Several Under-Studied Populations in the United States (PASSAGE)

AstraZeneca·interventional·Posted Apr 14, 2022·Updated Oct 14, 2025

In Brief

A Phase 4 clinical trial evaluating Tezepelumab for Asthma. Completed, enrolled 287 participants across 37 sites.

Detailed Summary

To asses effectiveness and safety of tezepelumab in adult and adolescent participants with severe asthma including several under-studied populations in the United States.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesUnited States
CollaboratorsParexel

Timeline

Phase 4CompletedFinished
2023202420252026
First PostedApr 14, 2022
Enrollment StartApr 29, 2022
Primary CompletionOct 1, 2025
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 4.2 years ago

Interventions

Tezepelumabdrug

Participants will be receiving subcutaneous injection of tezepelumab.